Alpha 2.0
Login Register
» Authors » Akram Saad

Akram Saad

Explore the profile of Akram Saad including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 101
Followers 0
Related Specialties
Oncology
Radiology
Gynecology & Obstetrics
Top 10 Co-Authors
Jeffrey Goldstein
Zvi Symon
Raanan Berger
Tima Davidson
Benjamin Spieler
Yaacov R Lawrence
Sarit Appel
Jair Bar
Sameh Daher
Damien Urban
Published In
Int J Gynecol Cancer
Am J Clin Oncol
Isr Med Assoc J
Pharmacoepidemiol Drug Saf
Gynecol Oncol Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitors
Peleg Hasson S, Shachar E, Brezis M, Saad A, Toledano B, Michaan N, et al.
Int J Gynecol Cancer . 2024 Jan; 34(4):559-565. PMID: 38242547
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) play a pivotal role in ovarian cancer management. With medical cannabis emerging as a novel component of supportive care, this study investigated the impact...
2.
Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery
Appel S, Bar J, Saad A, Marom E, Urban D, Onn A, et al.
Br J Radiol . 2023 Sep; 96(1152):20220763. PMID: 37751214
Objective: We hypothesized that driver mutations in epidermal growth factor receptor (EGFR) are associated with decreased pathologic response to neoadjuvant chemoradiation (NA-ChRT) in locally advanced non-small cell lung cancer (LA-NSCLC)....
3.
Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix
Peleg Hasson S, Felder S, Helpman L, Taylor A, Shalamov M, Abuakar S, et al.
Int J Gynecol Cancer . 2023 Mar; 33(5):683-691. PMID: 36963801
Objective: The use of chemoradiation in patients with stage IVB cancer of the cervix was evaluated to determine if definitive treatment offers benefit. Methods: A database of 546 patients with...
4.
Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer
Daher S, Zer A, Tschernichovsky R, Yacobi R, Barshack I, Tsabari S, et al.
Lung Cancer . 2023 Mar; 178:229-236. PMID: 36898331
Objectives: The identification and targeting of actionable genomic alterations (AGA) have revolutionized the treatment of cancer in general and mostly for non-small cell lung cancer (NSCLC). We investigated whether in...
5.
Real-world experience with capmatinib in exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
Illini O, Fabikan H, Swalduz A, Vikstrom A, Krenbek D, Schumacher M, et al.
Ther Adv Med Oncol . 2022 Jun; 14:17588359221103206. PMID: 35720834
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal-epithelial transition () exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor,...
6.
Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone
Saad A, Goldstein J, Appel S, Daher S, Urban D, Onn A, et al.
Thorac Cancer . 2022 May; 13(12):1763-1771. PMID: 35538909
Objective: Compare outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation and adjuvant durvalumab to historical controls treated with chemoradiation alone. Methods: The records of...
7.
Initial estimates of continuous positive airway pressure (CPAP) on heart volume, position and motion in patients receiving chest radiation
Weizman N, Baidun K, Goldstein A, Amit U, Saad A, Lawrence Y, et al.
Med Dosim . 2022 Mar; 47(2):191-196. PMID: 35256246
To evaluate effects of Continuous Positive Airway Pressure (CPAP) on cardiac position, volume, and motion in a cohort of patients receiving thoracic radiation therapy (RT). Patients underwent 3-dimensional (3D) and...
8.
Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?
Stern T, Peleg Hasson S, Saad A, Levanon K, Michaan N, Laskov I, et al.
Gynecol Oncol Rep . 2021 Oct; 38:100863. PMID: 34621946
Objective: To examine whether patients with both breast cancer (BC) and endometrial cancer (EC) have different features of disease, and whether the sequence of appearance of these tumors is correlated...
9.
A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer
Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, et al.
Oncologist . 2020 May; 25(9):787-792. PMID: 32430954
Background: Prostate cancer is a common malignancy of the elderly, and with the aging of the population, the need is growing for therapies suitable for this age group. Lutetium-177-prostate-specific membrane...
10.
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
Gadot M, Davidson T, Aharon M, Atenafu E, Malki A, Levartovsky M, et al.
Cancers (Basel) . 2020 May; 12(5). PMID: 32357427
Lutetium-177-PSMA ([177Lu]-PSMA-617), a radiolabeled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling targeted radiation therapy to metastatic prostate lesions. Our objective was to retrospectively analyze the...